Clin2
NCT07251556Possibly a fitNot yet recruiting

GLP-1 drug for psoriatic arthritis in overweight patients without diabetes

Psoriasis Arthritis

Treatments studied

Part of Bones, joints & muscles, Hormones & metabolism, Skin clinical trials.

This trial tests if a GLP-1 receptor agonist (a type of diabetes medication) can help treat psoriatic arthritis in people who are overweight but do not have diabetes. You might join if you have psoriatic arthritis, a high BMI, and you are of Chinese descent.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
40 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have psoriatic arthritis as diagnosed by a doctor
  • You are 18 or older and of Chinese descent
  • Your BMI is 25 or higher (overweight or obese)
  • You have not taken any GLP-1 medications in the past 6 months
  • You do not have diabetes, heart disease, pancreatitis, cancer, or liver/kidney problems
  • You are not pregnant, breastfeeding, or planning to become pregnant

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06937060Recruiting· Phase 3
Semaglutide for psoriasis and obesity

This trial tests if semaglutide, a medicine used for diabetes and weight loss, can help people with both psoriasis and obesity. You may qualify if you have moderate to severe psoriasis, a high body weight, and are of Chinese descent.

Hong Kong
NCT07401992Recruiting· Phase 4
Semaglutide for psoriasis and weight management

This trial tests if semaglutide, a diabetes and weight-loss medication, can improve psoriasis symptoms and reduce inflammation. It may be an option for people with both psoriasis and overweight or obesity, with or without diabetes.

Monterrey, N.L.
NCT07111494Recruiting· Phase 4
GLP-1 medication for psoriatic arthritis outcomes

This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.

Milwaukee, Wisconsin
NCT06909006Not yet recruiting· Phase 3
Semaglutide for type 1 diabetes with higher body weight

This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.

Hillerød, Denmark
NCT06908694Recruiting· Phase 4
GLP-1 drugs for weight management in prostate cancer

This trial tests if a GLP-1 receptor agonist (a type of diabetes drug that helps with weight loss) can help men with prostate cancer who are on hormone therapy (ADT) and have a high body mass index (BMI). It aims to see if it improves their health and outcomes.

Hamilton, Ontario
NCT07323134Not yet recruiting
Semaglutide for obesity and gut health

This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.

Hear when a new Psoriasis Arthritis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.